Subcutaneous delivery of poly(oxazoline) conjugates
AssigneeSerina Therapeutics, Inc.
InventorsRandall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
Life of this patent
Estimating the term…
Abstract
The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
Claims17
A polymer conjugate of the general formula (I),
- wherein,
- a is ran which indicates a random copolymer or block which indicates a block copolymer
- o is an integer from 1 to 50;
- m is an integer from 190 to 950;
- p is 1-18;
- R is hydrogen, alkyl or substituted alkyl;
- and
- Ag is a dopamine agonist selected from the group consisting of:
- rotigotine, pramipexole, quinagolide, fenoldopam, apomorphine, 5-OH-DPAT, ropinirole, pergolide, cabergoline, and bromocriptine.
A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system, the method comprising the step of administering to the subject an amount of a polymer conjugate, the polymer conjugate comprising a poly(oxazoline) polymer and an dopamine agonist, the dopamine agonist linked to the polymer by a releasable linker, the releasable linker cleavable in a subject and providing a sustained, controllable delivery of the dopamine agonist over a period of days to weeks.
A method for treating Parkinson's disease, the method comprising the step of administering to the subject an amount of a polymer conjugate, wherein the polymer conjugate has the structure
- wherein
- R is hydrogen, alkyl or substituted alkyl;
- p is 1 to 18;
- a is ran which indicates a random copolymer or block which indicates a block copolymer;
- o is an integer from 1 to 50;
- and
- m is an integer from 190 to 950.
Dependencies are inferred from the claim text.